A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone …
OBJECTIVE: ATN-224 (choline tetrathiomolybdate) is an oral Cu2+/Zn2+-superoxide
dismutase 1 (SOD1) inhibitor with preclinical antitumor activity. We hypothesized that ATN-
224 may induce antitumor effects as an antiangiogenic agent at low dose-levels while
possessing direct antitumor activity at higher dose-levels. The objective of this study was to
screen its clinical activity in patients with biochemically recurrent hormone-naïve prostate
cancer. METHODS: Biochemically-recurrent prostate cancer patients with prostate specific …
dismutase 1 (SOD1) inhibitor with preclinical antitumor activity. We hypothesized that ATN-
224 may induce antitumor effects as an antiangiogenic agent at low dose-levels while
possessing direct antitumor activity at higher dose-levels. The objective of this study was to
screen its clinical activity in patients with biochemically recurrent hormone-naïve prostate
cancer. METHODS: Biochemically-recurrent prostate cancer patients with prostate specific …